BridgeBio Pharma Debt to Equity Ratio 2018-2024 | BBIO
Current and historical debt to equity ratio values for BridgeBio Pharma (BBIO) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. BridgeBio Pharma debt/equity for the three months ending June 30, 2024 was 0.00.
| BridgeBio Pharma Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$1.88B |
$-1.08B |
-1.73 |
| 2024-03-31 |
$1.89B |
$-1.04B |
-1.82 |
| 2023-12-31 |
$1.89B |
$-1.34B |
-1.41 |
| 2023-09-30 |
$1.85B |
$-1.20B |
-1.55 |
| 2023-06-30 |
$1.85B |
$-1.35B |
-1.37 |
| 2023-03-31 |
$1.84B |
$-1.21B |
-1.52 |
| 2022-12-31 |
$1.87B |
$-1.24B |
-1.50 |
| 2022-09-30 |
$1.86B |
$-1.13B |
-1.65 |
| 2022-06-30 |
$1.88B |
$-1.01B |
-1.85 |
| 2022-03-31 |
$1.85B |
$-1.04B |
-1.78 |
| 2021-12-31 |
$1.88B |
$-0.87B |
-2.17 |
| 2021-09-30 |
$1.52B |
$-0.74B |
-2.06 |
| 2021-06-30 |
$1.54B |
$-0.46B |
-3.36 |
| 2021-03-31 |
$1.48B |
$-0.39B |
-3.81 |
| 2020-12-31 |
$0.60B |
$0.11B |
5.62 |
| 2020-09-30 |
$0.57B |
$0.22B |
2.65 |
| 2020-06-30 |
$0.58B |
$0.33B |
1.78 |
| 2020-03-31 |
$0.54B |
$0.45B |
1.20 |
| 2019-12-31 |
$0.16B |
$0.47B |
0.33 |
| 2019-09-30 |
$0.12B |
$0.52B |
0.23 |
| 2019-06-30 |
$0.00B |
$0.00B |
0.00 |
| 2019-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2018-12-31 |
$0.00B |
|
0.00 |
| 2018-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2017-12-31 |
$0.00B |
$0.00B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.791B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
